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Abstract
Background: Cdc5 (polo kinase/Plk1) is a highly conserved key regulator of the S. cerevisiae cell cycle from S-phase
until cytokinesis. However, much of the regulatory mechanisms that govern Cdc5 remain to be determined. Cdc5
is phosphorylated on up to 10 sites during mitosis. In this study, we investigated the function of phosphorylation
site T23, the only full consensus Cdk1 (Cdc28) phosphorylation site present.
Findings: Cdc5
T23A introduces a degron that reduces its cellular amount to undetectable levels, which are
nevertheless sufficient for normal cell proliferation. The degron acts in cis and is reversed by N-terminal GFP-
tagging. Cdk1 kinase activity is required to maintain Cdc5 levels during G2. This, Cdk1 inhibited, Cdc5 degradation
is APC/C
Cdh1 independent and requires new protein synthesis. Cdc5
T23E is hyperactive, and reduces the levels of
Cdc5 (in trans) and drastically reduces Clb2 levels.
Conclusions: Phosphorylation of Cdc5 by Cdk1 is required to maintain Cdc5 levels during G2. However,
phosphorylation of T23 (probably by Cdk1) caps Cdc5 and other CLB2 cluster protein accumulation, preventing
potential protein toxicity, which may arise from their overexpression or from APC/C
Cdh1 inactivation.
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Findings
Cdc5/polo kinase is a crucial player in cell-cycle regu-
lation from yeast to man, and the processes and sub-
strates it regulates have been extensively investigated.
Cdc5 regulates numerous cell cycle events, including
promoting the destruction of the Cdk1-Clb2 inhibitor
Swe1 [1], CLB2 cluster transcription (including itself)
[2], spindle-pole body separation [3], spindle position-
ing [4], microtubule organization [5], recovery from
hydroxyurea [6], APC/C activation [7], mitotic exit [8],
cytokinesis [9,10], Cdc14 localization [11,12] and APC/
C
Cdh1 inhibition [13]. However, the regulation of Cdc5
itself remains relatively uncharacterized. In response to
DNA damage, Cdc5 is inhibited by Rad53 mediated
phosphorylation at an unidentified site [14,15]. Phos-
phorylation of T242 by Cdk1 has been reported to be
essential for viability and mitotic activity [16], though
this is disputed [1]. Nine other sites have been
reported to be phosphorylated during mitosis [16], of
which one, T29, when mutated to alanine stabilizes
Cdc5 during G1 [17]. Four of these sites are clustered
within the first 70 amino acids of Cdc5, suggesting
modification of this region may be of importance to
the regulation of Cdc5.
Cdc5 stability is regulated by phosphorylation of T23
Cdc5 degradation by the APC/C
Cdh1 ubiquitin ligase is
mediated by two D-boxes (RxxL) located within the N-
terminal 70 amino acid region. Cdc5 levels oscillate dur-
ing the cell cycle, from low in G1 and S-phase to ele-
vated in G2/M [7,18]. Cdc5 levels in cdh1Δ cells are
invariable throughout the cell cycle and comparable to
levels of Cdc5 in wt metaphase cells. (Figure 1A). Phos-
phorylation on or adjacent to APC/C specific D-boxes
could have a role in the regulation of substrate degrada-
tion. Cdc5 has several known phosphosites in its N-
terminal part that could be involved in such a regula-
tion. We have previously reported that a mutation of
the T29 phosphosite dramatically stabilizes Cdc5 and
completely eliminates its APC/C specific degradation
[17]. In this report we studied the T23 phosphosite.
Cells expressing cdc5
T23A [16] as the sole Cdc5,
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Figure 1 A: The T23A mutation destabilizes Cdc5. Wild-type and cdh1Δ cells were arrested in S-phase (0.2 M hydroxyurea), metaphase (5 μg/
ml nocodazole) or early G1 (1 μg/ml rapamycin) for 2.5h and probed with anti-Cdc5 (Santa Cruz y300). B: Cdc5Δ cells [3] expressing Cdc5 from
the indicated plasmids [16] were arrested in S-phase (0.2 M hydroxyurea), metaphase (5 μg/ml nocodazole) or early G1 (1 μg/ml rapamycin) for
2.5h. C: A full blot was probed with anti-Cdc5 to check for the possibility of proteolytic processing of cdc5
T23A. Cells were released from S-phase
and rearrested at metaphase. D: Cdc5Δ cells expressing GFP-Cdc5
WT [3] or GFP-cdc5
T23A were synchronized in S-phase, released and rearrested at
metaphase. E: Cdc5-13myc cells [3] expressing Cdc5
WT or cdc5
T23A were synchronized in S-phase, released and rearrested at metaphase.
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drial, and tubulin dynamics and undergo normal
cytokinesis.
The abundance of wild type Cdc5 and cdc5
T23A pro-
tein during the cell cycle was examined by treating cells
with hydroxyurea (S-phase arrest), nocodazole (meta-
phase arrest), or rapamycin (early G1 arrest). Curiously,
Cdc5
T23A protein was undetectable under all these con-
ditions (Figure 1B). Examination of whole blots with
anti-Cdc5 ruled out proteolytic processing (Figure 1C).
Moreover cdc5
ΔN70, which lacks this phosphorylation
site [12], migrates at the expected size (Rosella Visintin,
personal communication). As Cdc5 is an essential pro-
tein we assume that cdc5
T23A cells still express it, albeit
at an undetectable level.
The lack of detection of this essential protein could be
due to two reasons - the first is that the antibody used
does not bind to this mutant. We considered this unli-
kely, as the antibody used is a polyclonal antibody
against the entire C-terminus of Cdc5. The other possi-
bility is that the T23A mutation is, or has, introduced a
degron. To test these ideas we expressed GFP-Cdc5
WT
[3] or GFP-cdc5
T23A from the Cdc5 promoter either as
the sole Cdc5 or in addition to an endogenous copy of
Cdc5. Surprisingly GFP-cdc5
T23A was detectable, both
by anti-GFP and by anti-Cdc5 (Figure 1D) and accumu-
lated normally. This indicates that the T23A mutation
indeed introduced a degron and that the degron was
masked by the N-terminal fusion of the GFP protein.
To determine whether the instability of cdc5
T23A has
an effect in trans - on other copies of Cdc5, cdc5
T23A
was expressed in cells containing endogenous Cdc5
13myc,
which has reduced electrophoretic mobility. Accumula-
tion of endogenous Cdc5
13myc,a n do fC l b 2 ,w a su n a f -
fected by the presence of cdc5
T23A (Figure 1E),
suggesting that this mutation acts only in cis.
The degradation of Swe1, a kinase that phosphory-
lates Cdk1 on Y19 and inhibits its activity, requires
Cdc5 [19]. In fact Swe1 degradation is one of the two
essential functions of Cdc5 [3]. As cdc5
T23A protein
levels were undetectable, we used Swe1 levels as a
measure for Cdc5 activity. Cells were synchronized
with hydroxyurea and released into nocodazole. Sur-
prisingly, Swe1 levels were reduced in cdc5
T23A cells,
even in hydroxyurea, and Swe1 was rapidly eliminated
upon release from S-phase arrest (Figure 2A). Phos-
phorylation of Cdk1 on Y19 was likewise diminished,
as could be expected from the reduced levels of Swe1.
Swe1 degradation thus indicates that the cdc5
T23A pro-
tein must be present and active (and possibly even
hyperactive) in cells. Accumulation of Clb2 was normal
and, as we have already shown above, cdc5
T23A was not
detected.
Cdk1 is required for maintenance of Cdc5 levels in G2
T23 is the only full consensus Cdk1 phosphorylation site
of Cdc5 (S/T-P-x-K/R) and is phosphorylated during
mitosis [16]. Although Cdk1-Clb2 activity promotes
transcription of Cdc5, Clb2 and other CLB2 cluster
genes [20-22], it has not yet been ascertained whether
maintenance of Cdc5 protein levels during G2/M is also
Cdk1 activity dependent. Cells carrying the 1NM-PP1
analogue-inhibitable cdk1
as1 [23] were synchronized in
S-phase with hydroxyurea and released for 100 minutes
into G2 to allow Cdc5 to reach near maximum levels
before the addition of 0.5 μM 1NM-PP1. Cells addition-
ally overexpressed the Cdh1 inhibitor Acm1 [24] to pre-
vent possible APC/C
Cdh1 mediated destruction of Cdc5
[7,14]. Upon inhibition of Cdk1 activity, Cdc5 levels
rapidly declined whereas levels of Clb2 remained stable
(Figure 3A). Swe1 gradually increased in abundance in
1NM-PP1 treated cells. Therefore, Cdk1 activity seems
to be required for maintenance of Cdc5 levels during
G2, possibly by phosphorylation of Cdc5 on T23. The
fact that cdk1 inhibition did not completely eliminate
cdc5 levels as observed for the T23A mutation, can be
due to the fact that cdc5 was initially phosphorylated
and that this phosphorylation partially persisted for the
duration of the experiment. It is also possible that other
kinases can, to some extent, phosphorylate this site.
Even if less likely it cannot be ruled out that the T23
residue is a structurally important residue whose muta-
tions render general protein instability.
The decline in Cdc5 levels was prevented by addition
of cycloheximide (Figure 3B), indicating that new pro-
teins must be synthesized for the elimination of Cdc5 in
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Figure 2 Swe1 is degraded faster in cdc5
T23A cells. Cdc5Δ cells
expressing Cdc5
WT or cdc5
T23A were synchronized in S-phase,
released and rearrested at metaphase. Rabbit anti-Clb2 was a kind
gift from A. Amon. Swe1 was 6myc tagged by integration of
pRS305 Swe1-6myc cut with SnaBI [26] and detected using 9E10
mouse anti-myc (a kind gift of M. Goldberg).
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Cdh1 destruction mechanism may also account for
the residual instability seen in Cdc5 with both D-boxes
mutated or in cdh1Δ cells [18], whilst Cdc5 with the
first 70 amino acids deleted (cdc5ΔN70) is completely
stable in G1 [7,12].
Phosphorylation of T23 regulates Cdc5 accumulation
We next examined the phospho-mimicking cdc5
T23E
mutant [16]. cdc5
T23E cells (as their sole Cdc5) grew
with normal morphology, separation, tubulin and septin
dynamics (data not shown). S-phase arrested cdc5
T23E
cells had reduced Swe1 levels and activity, and upon
release Swe1 levels declined more rapidly than in wild-
type cells, suggesting increased Cdc5 activity (see [1]).
Interestingly, Clb2 was absent from these cells, and
Cdc5 levels did not increase after 1 hour from release
from S-phase arrest (Figure 4A). In contrast to cdc5
T23A,
t h ep r e s e n c eo fcdc5
T23E affects Cdc5 levels in trans,
reducing Cdc5 accumulation by approximately 50% (Fig-
ure 4B). N-terminal tagging of cdc5
T23E with GFP did
not suppress this reduced accumulation phenotype (Fig-
ure 4C). Mutating a threonine (T) to glutamic acids (E)
is generally considered a phospho-mimicking mutation.
It is however hard to assess whether the effect of gluta-
mic acid is like genuine threonine phosphorylation. In
many cases such a mutation has no such effect, and
behaves like a non-phosphorylatable alanine. The effect
we observed here is clearly not like that of non-phos-
phorylatable alanine, as cdc5
T23E is considerably more
stable than the undetectable cdc5
T23A. However as
cdc5
T23E i sn o ta ss t a b l ea sw tc d c 5a n dl e a d st os o m e
other non-wt effects like clb2 disappearance, we might
observe here an intermediate effect. It is also possible
that phospho-mimicking of this site has one effect on
stability and another on activation. The T23 site does
not fall within the kinase domain of Cdc5 and its
enhanced apparent activity is likely due to modified
interactions with other proteins, rather than intrinsic
changes in its kinase activity.
Conclusions
APC/C
Cdh1 substrate proteins accumulate to maximal
levels in metaphase and are either absent or present at
much lower levels during the rest of the cell cycle. In
cdh1Δ cells the level of these proteins is, in most cases,
uniformly high throughout the cell cycle. Strikingly this
level is comparable to their metaphase level in wild type
cells. This observation suggests that some additional
mechanisms are likely to cap the level of these proteins,
in addition to APC/C
Cdh1 specific degradation. In this
report, we have uncovered a potential mechanism that
provides a negative feedback regulation of Cdc5 levels, a
toxic protein when overexpressed [25], enabling cells to
tolerate mild overexpression of Cdc5 (D. Morgan, perso-
nal communication). This mechanism is two-fold.
Firstly, Cdc5 stability in G2 is Cdk1 kinase activity
dependent. In the absence of Cdk1 kinase activity, Cdc5
is degraded by a novel, APC/C
Cdh1 independent
mechanism that requires protein synthesis and which
may account for the residual instability of D-box
mutated Cdc5 [18]. Secondly, phosphorylation of T23 of
Cdc5, presumably by Cdk1 [16], limits the rate and
maximal accumulation of Cdc5, Clb2 and possibly other
CLB2 cluster proteins. A potential mechanism could be
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Figure 3 A: Cdk1 is required for maintenance of Cdc5 levels in
G2. Cdk1
as1 [23] cells were synchronized in S-phase with 0.2 M
hydroxyurea and released for 100 minutes into G2 (Cdc5 levels are
near maximal) in media containing 5 μg/ml nocodazole. 0.5 μM1
NM-PP1 (from a 1 mM stock in DMSO) or an equivalent volume of
DMSO was added. B: As A, except that at 100 minutes 200 μg/ml
cycloheximide (CHX) was also added to both samples. The activity
of CHX is confirmed by the fact that levels of Clb2 do not continue
to rise as happens in its absence (Figure 3A).
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Figure 4 Phosphorylation of T23 regulates Cdc5 accumulation. A: cdc5Δ cells [3] expressing Cdc5
WT or cdc5
T23E [16] were synchronized in S-
phase, released and rearrested at metaphase. B: Cdc5-13myc cells [3] expressing Cdc5
WT or cdc5
T23E [16] were synchronized in S-phase, released
and rearrested at metaphase. C: cdc5Δ cells [3] expressing eGFP-Cdc5
WT or eGFP-cdc5
T23E were synchronized in S-phase, released and rearrested
at metaphase.
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T23E to switch off CLB2 cluster transcription
when a desirable level of CLB2 cluster proteins is
reached.
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